Sacubitril/valsartan, an angiotensin receptor-neprilysin inhibitor (ARNI), combines renin-angiotensin blockade with natriuretic peptide augmentation and has proven antihypertensive efficacy; however, data about its real-world use during the acute phase of ICH remain limited.<h4>Methods</h4>We performed a single-center retrospective cohort study of consecutive patients with acute ICH and untreated refractory hypertension. The gene discussed is REN; the disease is Hypertension.